Differential effects of BTK inhibitors ibrutinib and zanubrutinib on NK-cell effector function in patients with mantle cell lymphoma

Haematologica. 2020 Jan 31;105(2):e76-e79. doi: 10.3324/haematol.2019.220590. Print 2020.

Thijs W H Flinsenberg¹, Charnelle C Tromedjo², Nan Hu³, Ye Liu³, Yin Guo³, Kevin Y T Thia², Tahereh Noori², Xiaomin Song³, Han X Aw Yeang^{2

4}, Daniela G Tantalo², Sasanka Handunnetti^{5

6}, John F Seymour^{5

6}, Andrew W Roberts^{5

6}, David Ritchie^{5

6

7}, Rachel Koldej^{5

7}, Paul J Neeson^{2

4}, Lai Wang³, Joseph A Trapani^{2

4}, Constantine S Tam^{8

6}, Ilia Voskoboinik^{1

4}

¹ Cancer Immunology Program and Rosie Lew Immunotherapy Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia thijsflinsenberg@gmail.com ilia.voskoboinik@petermac.org constantine.tam@petermac.org.
² Cancer Immunology Program and Rosie Lew Immunotherapy Program, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
³ BeiGene LTD, Beijing, China.
⁴ Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.
⁵ Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Parkville, Victoria, Australia.
⁶ Department of Clinical Haematology, Peter MacCallum Cancer Centre & Royal Melbourne Hospital, Melbourne, Victoria, Australia.
⁷ The ACRF Translational Research Laboratory; Royal Melbourne Hospital, Parkville, Victoria, Australia.
⁸ Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Parkville, Victoria, Australia thijsflinsenberg@gmail.com ilia.voskoboinik@petermac.org constantine.tam@petermac.org.

No abstract available

Publication types